**INTRODUCTION**

Enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+ER+ advanced breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a Phase 2 clinical study.

**RESULTS**

**Phase 2 clinical trial (G200802) efficacy summary**

- **Efficacy results:** BCIRG111, best overall tumor responses (BOR) by central pathology classification in patients with metastatic breast cancer:
  - 9 mg cohort (p<0.001)
  - 18 mg cohort (p=0.25) partial responses:
  - 10% (9 mg)
  - 8% (18 mg)

**Efficacy summary**

- **Objective tumor responses:**
  - 9 mg cohort
  - 18 mg cohort

- **Key patient demographics:**
  - **Number of evaluable patients:** 50 (9 mg) 52 (18 mg)
  - **Central AR status assessed:**

**CONCLUSIONS**

- In the evaluable patients with measurable metastatic AR+ER+ MBC who had progressed following treatment with a CDK 4/6 inhibitor (palbociclib), enobosarm treatment resulted in a clinical benefit rate of 50%, and the best objective tumor response was 30% including 2 CRs and 1 PR. The overall mean radiographic PFS in the 9 mg cohort was 10.0 months.

- Overall, in this Phase 2 study, enobosarm demonstrated clinical benefit with objective tumor responses in the treatment of women with AR+ ER+ metastatic breast cancer.

- **Enobosarm appears safe and well tolerated without critical effects**
  - **Most observed adverse events are grade 1 and 2**
  - **Overall:** 11% of patients had grade ≥3 adverse events

**Phase 2 clinical trial (G200802): safety**

- **Enobosarm was well tolerated; majority of events were Grade 1 and 2**
  - **Summary of safety data patients (ITT):**

**Evaluation of phase 4**

- **Efficacy summary**
  - **Number of evaluable patients:** 50 (9 mg) 52 (18 mg)

**Overall:** 11% of patients had grade ≥3 adverse events

**Safety**

- **Overall:** 11% of patients had grade ≥3 adverse events

**Phases 2 clinical trial (G200802):**

- **Enobosarm was well tolerated; majority of events were Grade 1 and 2**

**Summary of safety data patients (ITT):**

- **Overall:** 11% of patients had grade ≥3 adverse events